1. |
|
|
2. |
- Daniele, B, et al.
(author)
-
Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study
- 2015
-
In: Future oncology (London, England). - : Future Medicine Ltd. - 1744-8301 .- 1479-6694. ; 11:18, s. 2553-2562
-
Journal article (peer-reviewed)abstract
- SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. Patients & methods: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. Results: Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. Conclusion: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.
|
|
3. |
|
|
4. |
|
|